A5066381176- Bladder and Urothelial Cancer Treatments
- Urinary Bladder and Prostate Research
- Prostate Cancer Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Pelvic floor disorders treatments
- Urinary and Genital Oncology Studies
- Hormonal and reproductive studies
- Urinary Tract Infections Management
- Urological Disorders and Treatments
- Epigenetics and DNA Methylation
- Bone health and treatments
- Radiopharmaceutical Chemistry and Applications
- Cancer Research and Treatments
- Amino Acid Enzymes and Metabolism
- Esophageal Cancer Research and Treatment
- Urologic and reproductive health conditions
- Sexual function and dysfunction studies
- Cancer Diagnosis and Treatment
- Medical Imaging Techniques and Applications
- Immunotherapy and Immune Responses
- Venous Thromboembolism Diagnosis and Management
- Cancer, Lipids, and Metabolism
- Genital Health and Disease
- Cancer Immunotherapy and Biomarkers
- Ureteral procedures and complications
European Association of Urology
2014-2025
Radboud University Nijmegen
2000-2024
Radboud University Medical Center
2002-2024
Rijnstate Hospital
2022
Humanitas University
2022
Tampere University
2006
Tampere University Hospital
2006
Southmead Hospital
1997-1999
University of Bristol
1997-1999
Gentofte Hospital
1999
To compare the efficacy and tolerability of alpha 1 A-subtype selective drug tamsulosin with nonsubtype-selective agent alfuzosin in treatment patients lower urinary tract symptoms (LUTS) suggestive bladder outlet obstruction (BOO), often termed symptomatic benign prostatic hyperplasia (BPH).The study comprised 256 enlargement LUTS BOO (symptomatic BPH) who received 0.4 mg once daily or 2.5 three times during 12 weeks treatment. The response was assessed by measurements maximum flow rate...
Prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed (CT) is useful for selected clinical indications in patients with prostate cancer (PCa) but it may have broader utility owing to the emergence of lutetium-177-PSMA-617 ([177Lu]Lu-PSMA) therapy. However, robust data regarding impact PSMA PET/CT on patient management and treatment are lacking, many areas, role next-generation imaging has not been defined.To assess expert opinion use PSMA-based therapy develop...
No AccessJournal of UrologyClinical Urology: Original Article1 Mar 1995Original Articles: Bladder Cancer: A Randomized Study Intravesical Mitomycin C, Bacillus Calmette-Guerin Tice and RIVM Treatment in pTa-pT1 Papillary Carcinoma Situ the Peter D.J. Vegt, J. Alfred Witjes, Wim P.J. H. Doesburg, Frans M.J. Debruyne, A.P.M. van der Meijden, E. David Crawford VegtPeter Vegt , WitjesJ. Witjes WitjesWim DoesburgWim Doesburg DebruyneFrans Debruyne MeijdenA.P.M. Meijden CrawfordE. View All Author...
Despite the lack of evidence in literature for close relationships between lower urinary tract symptoms and bladder outlet obstruction, majority urologists rely on symptomatology when selecting patients prostatic surgery. We investigated a wide range from ICSmale questionnaire results urodynamic pressure flow studies. evaluated 933 with suggestive obstruction 12 countries who participated ICS-"BPH" study Spearman rank correlation coefficients were obtained measures obstruction. There was...
To evaluate the outcome and durability of high-energy transurethral microwave thermotherapy (HE-TUMT) in comparison with resection prostate (TURP).Fifty-two patients BPH lower urinary tract symptoms were randomized treated either by TURP (21 patients; mean volume 45 mL, SD 15) or HE-TUMT (31 patients, 43 12). Long-term results obtained at a (SD) follow-up 2.4 (0.5) years.During follow-up, symptomatic improvement stabilized 56% after TUMT 74% TURP. The maximum flow rate increased 62% 105%...
Background and objectiveThe European, prospective, multicenter SATURN registry was developed to analyze surgical devices for male stress urinary incontinence. The primary objective is the cure rate during follow-up.MethodsEfficacy, complications, patient-reported outcomes, prognostic factors are being analyzed at various intervals 10-yr follow-up. results 1-yr follow-up presented here.Key findings limitationsThe cohort included 1046 patients (mean age 70 yr) from 28 centers in nine...
Results of a randomized prospective study are reported in which mitomycin C, Tice bacillus Calmette-Guerin (BCG) and RIVM-BCG were compared 437 patients with primary or recurrent pTa pT1 bladder tumors, including carcinoma situ. The followup (or time study) varied from 2 to 81 months (mean 36 months). After complete transurethral resection all visible tumors the treated 30 mg. C once week for 4 consecutive weeks thereafter every month total 6 months, 5 x 10(8) colony-forming units BCG weeks....
We study toxicity and efficacy of sequential intravesical therapy with mitomycin C bacillus Calmette-Guerin (BCG) in patients intermediate or high risk superficial bladder cancer compared to the use alone.Patients papillary carcinoma situ were randomized after transurethral resection between 4 weekly instillations 40 mg. followed by 6 BCG (group 1, 90 patients) 10 2, 92 patients).The frequency bacterial chemical cystitis, other local side effects was similar both groups. Allergic reactions,...
We compared the outcome of transurethral resection prostate and high energy microwave thermotherapy in patients with benign prostatic hyperplasia.Of 52 symptomatic hyperplasia 21 (mean age plus or minus standard deviation 69.6 +/- 8.5 years) were treated 31 69.3 5.9 thermotherapy. Patients assessed using Madsen symptom score, measurements voiding parameters, transrectal ultrasound cystometry, including pressure-flow analyses. Examinations repeated at fixed intervals for up to 12 months after...
Objective To determine if, in patients with lower urinary tract symptoms (LUTS), measurement of the transition zone (TZ) prostate by transrectal ultrasonography (TRUS) and ratio between TZ volume total (TZ index) correlates better clinical urodynamic investigations than alone. Patients methods In total, 150 consecutive LUTS underwent a standardized screening programme including International Prostate Symptom Sore (IPSS), physical examination, TRUS pressure‐flow studies. The were assessed...
To develop a model to predict recurrence for patients with intermediate-risk (IR) non-muscle-invasive bladder cancer (NMIBC) treated intravesical chemotherapy which can be challenging because of the heterogeneous characteristics these patients.Data from three Dutch trials were combined. Patients according IR definition EAU guideline 2013 included. Uni- and multivariable Cox regression selection methods used identify predictors at 1, 2, 5 years. An easy-readable table probabilities was...